{
  "Disease": [
    {"role": "user", "content": "Please identify the \"Disease\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Disease\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: Isoproterenol sensitivity was determined as the intravenous dose that increased heart rate by 25 bpm ( CD25 ) and this was increased from 1 . 8 + / - 0 . 3 micrograms after placebo to 38 . 9 + / - 8 . 3 micrograms after propranolol and 8 . 3 + / - 1 . 7 micrograms after atenolol .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| None identified in the paragraph |\n\nThe paragraph is discussing the results of a study on Isoproterenol sensitivity, but it does not mention any specific diseases. It only mentions the drugs used in the study: placebo, propranolol, and atenolol."},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Disease\" and present the valid entities as a Markdown table with one column \"Disease\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| None identified in the paragraph |\n\nThe paragraph is discussing the results of a study on Isoproterenol sensitivity, but it does not mention any specific diseases. It only mentions the drugs used in the study: placebo, propranolol, and atenolol. These are not diseases, but rather interventions or treatments."}
  ],
  "Chemical": [
    {"role": "user", "content": "Please identify the \"Chemical\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Chemical\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: Isoproterenol sensitivity was determined as the intravenous dose that increased heart rate by 25 bpm ( CD25 ) and this was increased from 1 . 8 + / - 0 . 3 micrograms after placebo to 38 . 9 + / - 8 . 3 micrograms after propranolol and 8 . 3 + / - 1 . 7 micrograms after atenolol .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| Isoproterenol |\n| Propranolol |\n| Atenolol |\n\nIsoproterenol: Isoproterenol sensitivity\n\nPropranolol: propranolol\n\nAtenolol: atenolol"},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Chemical\" and present the valid entities as a Markdown table with one column \"Chemical\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| Isoproterenol |\n| Propranolol |\n| Atenolol |\n\nIsoproterenol: Isoproterenol (mentioned as the substance whose sensitivity is being determined)\n\nPropranolol: propranolol (mentioned as the name of the drug)\n\nAtenolol: atenolol (mentioned as the name of the other drug)"}
  ]
}